BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong WW, Haines A, Farhang Zangneh H, Shah H. Can we afford not to screen and treat hepatitis C virus infection in Canada? CanLivJ 2018;1:51-65. [DOI: 10.3138/canlivj.1.2.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Chan J, Kim JJ, Barrett BK, Hamadeh A, Feld JJ, Wong WWL. Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat 2021;28:260-7. [PMID: 33065774 DOI: 10.1111/jvh.13419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hamadeh A, Haines A, Feng Z, Thein HH, Janjua NZ, Krahn M, Wong WWL. Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies. J Viral Hepat 2020;27:1419-29. [PMID: 32810886 DOI: 10.1111/jvh.13373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]